Genmab | New Jersey's talent pool is a huge pull for Genmab. New Jersey has: 🔬 The highest concentration of scientists and engineers in the country 🎓 42% of... | By Choose New Jersey, Inc. | Facebook
Erin Henitz - Senior Director, Global Head of Precision Medicine Operations & Diagnostics - Genmab | LinkedIn
![Biotech company to move to former Bristol-Myers Squibb campus in Plainsboro – Princeton, NJ local news Biotech company to move to former Bristol-Myers Squibb campus in Plainsboro – Princeton, NJ local news](https://planetprinceton.com/wp-content/uploads/2019/07/777-Scudders-Mill-03.jpg)
Biotech company to move to former Bristol-Myers Squibb campus in Plainsboro – Princeton, NJ local news
![Genmab on X: "Genmab is a proud sponsor of @JAofNJ's Junior Achievement Inspire Virtual Career Expo in New Jersey, which aims to promote the importance of #education and highlight potential #career opportunities Genmab on X: "Genmab is a proud sponsor of @JAofNJ's Junior Achievement Inspire Virtual Career Expo in New Jersey, which aims to promote the importance of #education and highlight potential #career opportunities](https://pbs.twimg.com/media/E13JwdHWUAEYqRR.png)
Genmab on X: "Genmab is a proud sponsor of @JAofNJ's Junior Achievement Inspire Virtual Career Expo in New Jersey, which aims to promote the importance of #education and highlight potential #career opportunities
![Princeton Catalysis Initiative signs agreement with Genmab to forge strong community bond | Corporate Engagement & Foundation Relations Princeton Catalysis Initiative signs agreement with Genmab to forge strong community bond | Corporate Engagement & Foundation Relations](https://partnerships.princeton.edu/sites/g/files/toruqf726/files/styles/freeform_1440w/public/2022-02/Lab%20Shot%201.jpg?itok=plx1A5Gx)
Princeton Catalysis Initiative signs agreement with Genmab to forge strong community bond | Corporate Engagement & Foundation Relations
![Seagen - Seagen and Genmab Announce FDA Accelerated Approval for TIVDAK™ (tisotumab vedotin-tftv) in Previously Treated Recurrent or Metastatic Cervical Cancer Seagen - Seagen and Genmab Announce FDA Accelerated Approval for TIVDAK™ (tisotumab vedotin-tftv) in Previously Treated Recurrent or Metastatic Cervical Cancer](https://mms.businesswire.com/media/20210920005921/en/906425/4/Tivdak_Carton_w_Vial.jpg)
Seagen - Seagen and Genmab Announce FDA Accelerated Approval for TIVDAK™ (tisotumab vedotin-tftv) in Previously Treated Recurrent or Metastatic Cervical Cancer
![Princeton Catalysis Initiative signs agreement with Genmab to forge strong community bond | Corporate Engagement & Foundation Relations Princeton Catalysis Initiative signs agreement with Genmab to forge strong community bond | Corporate Engagement & Foundation Relations](https://partnerships.princeton.edu/sites/g/files/toruqf726/files/styles/freeform_750w/public/news/20201009-genmab-princeton-team-dscf4090-edit.jpg?itok=zoAj8ljE)